Charles River Laboratories International (CRL) As Faster Cell Banking Fuels A Modest Undervalued View
Event driven look at Charles River Laboratories International
Charles River Laboratories International (CRL) is back in focus after launching rapid cell banking programs that aim to cut cell bank production timelines by 40% compared with the typical 20 week industry standard.
Recent trading has been choppy. The share price is down 7.12% over the past month but up 30.38% over 90 days and 37.01% year to date, while the 1 year total shareholder return of 85.57% signals strong longer term momentum around Charles River Laboratories International as it rolls out new offerings and steps up conference visibility.
Scan for other contract research and advanced therapy partners moving on similar catalysts by reviewing the hand picked list of solid balance sheet and fundamentals (23 results) alongside Charles River Laboratories International.
After a near 86% one year total return and a share price only about 3% below the average analyst target yet roughly 7% under one fair value estimate, is the market being too cautious on Charles River Laboratories International or simply realistic about the risks?
Most Popular Narrative: 2% Undervalued
Charles River Laboratories International last closed at $277.33, slightly below a widely followed fair value estimate of $282.43 that uses an 8.5% discount rate and long term earnings forecasts as its base case.
The company's ongoing diversification and enhancement of its capabilities through investments in new approach methodologies (NAMs), automation, and digitalization positions it to benefit from industry shifts toward more complex and high-value testing, while also mitigating risks from regulatory and client preferences away from animal testing, improving operational efficiency and supporting future margin stability.
See why 4 investors see Charles River Laboratories International as 2% undervalued.
Result: Fair Value of $282.43 (UNDERVALUED)
Still, the Charles River Laboratories International story could change quickly if demand for animal based studies weakens faster than expected or if pricing pressure cuts into margins.
Find out about the key risks to this Charles River Laboratories International narrative.
Next Steps
Mixed views like these around Charles River Laboratories International are exactly where thoughtful investors do their best work, so move quickly, review the full picture, and then judge it for yourself with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Charles River Laboratories International?
If Charles River Laboratories International has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted searches that surface fresh opportunities fast.
- Target potential mispricing by scanning companies that combine quality metrics with attractive valuations through the 30 high quality undervalued stocks.
- Prioritize resilience and support steadier sleep by assessing companies screened for lower risk profiles using the 31 resilient stocks with low risk scores.
- Spot underfollowed potential opportunities early by reviewing the 16 high quality undiscovered gems before the crowd shows up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com